# Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html) · 2026-11-10 · Medicine
Page: https://themorning.science/story/prostate-cancer-drug-combination-adds-toxicity-without-clear-benefit-for-tumors-835610569d96bf0a
Kind: research · Impact: medium

## In brief

- ZZ-FIRST is a prospective, multicenter, randomized phase 2 clinical trial led by the Vall d'Hebron Institute of Oncology's Prostate Cancer Group.
- The trial evaluated enzalutamide, an androgen receptor pathway inhibitor (ARPI), combined with a poly(ADP-ribose) polymerase inhibitor (PARPi).
- For tumors lacking targetable mutations, the combination added toxicity without a clear benefit.

## Why it matters

It is a randomized trial result indicating that adding a PARP inhibitor to enzalutamide does not clearly help patients whose tumors lack targetable mutations, while increasing side effects.

## Coverage

- [Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations](https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html) — Medical Xpress - latest medical and health news stories, 2026-11-10

Tags: prostate cancer, clinical trial, enzalutamide, parp inhibitor, toxicity

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science